



D Thurtle¹, D Greenberg², LS Lee³, HH Huang³, PD Pharoah^{4*} & VJ Gnanapragasam^{1*}

- 2. National Cancer Registration and Analysis Service, Public Health England
- 3. Department of Urology, Singapore General Hospital
- 4. Centre for Cancer Genetic Epidemiology, Department of Public Health, University of Cambridge

BACKGROUND

 Prognostic stratification is the cornerstone of management in nonmetastatic prostate cancer (PCa)

• Existing prognostic models use inadequate surrogates for survival, stratify by broad groups and use heavily treated/screened cohorts.

• To address this unmet need for a modern personalised tool, we developed PREDICT: *Prostate* which contextualizes PCa-specific mortality (PCSM) against other mortality, and estimates treatmentimpact on survival.

PATIENTS & METHODS

• The analytic cohort was composed of 10,089 men diagnosed v PCa between 2000 and 2010 in Eastern England from the UK National Cancer Registration and Analysis Service (Table 1).

- Data were randomly split 70:30 into development and validation cohorts
- Separate multivariable Cox models were built for 15-year PCSM and non-prostate cancer mortality(NPCM) with fractional polynomials used to fit continuous variables and baseline hazards.
- Biopsy characteristics were assessed within a sub-cohort
- Model performance was assessed by area under the ROC curve (AUC) and Chi-Square goodness-of-fit¹.

• A Singaporean cohort of 2,546 men represented an additional validation set of different ethnicity and geography. (Table 1)

Table 1: Baseline coho	rt characteristics	amongs	t the BK and Sing	apore
cohorts			ability	
	Eastern England	%	Singapore	%
Total Subjects	10,089	-		-
Time at risk (years)	82,944	-	^{ਸ਼ੁੱਛ} 2,546 ² 12,316	-
Median f/u (years)	9.8	-	5.1	-
PCa Deaths within 10 yrs	1030	-	105	-
Non PCa deaths within 10yrs	2246	-	225	-
Total Deaths within 10yrs	3276	-	330	-
Age (mean)	69.9	-	66.1	-
PSA (mean)	18.4	-	15.7	-
Grade group:				
1	3328	33.0	1126	44.2
2	3017	29.9	723	28.4
3	1486	14.7	326	12.8 <u></u>
4	1032	10.2	170	12.8 Ai 6.7 Seusitivity 7.9 S
5	1226	12.2	201	7.9
Clinical T-stage:				
1	5421	53.7	1625	63.8
2	3213	31.8	660	25.9
3	1378	13.7	244	9.6
4	77	0.8	17	0.7
Primary Treatment:				
Radical Prostatectomy	1419	14.1	1012	39.7
Radiotherapy	3495	34.6	823	32.3
ADT Monotherapy	3178	31.5	164	6.4
Conservative Management	1997	19.8	538	21.1
Missing/HIFU	0	0.0	9	0.4


An individualised pre-treatment prognostic model for survival in non-metastatic prostate cancer

1. Academic Urology Group, Department of Surgery, University of Cambridge, UK & Cambridge University Hospitals NHSFT

*Equal contribution

with

	Prostate Cancer Specific Mortal				
	HR	95%CI	Р		
Age FP (age/10)^3 -341.16	1.003	1.002-1.003	0.000		
PSA FP In((psa+1)/100)+1.6364	1.204	1.092-1.328	0.000		
Grade group					
1	1.00	-	-		
2	1.32	1.06-1.65	0.01		
3	1.73	1.36-2.19	0.00		
4	2.10	1.63-2.69	0.00		
5	3.93	3.15-4.89	0.00		
T stage					
1	1.00	-	-		
2	1.18	1.01-1.37	0.04		
3	1.49	1.23-1.80	0.00		
4	1.88	1.14-3.13	0.01		
Percentage positive cores (P	PPC)				
<50%	0.54		0.00		
≥50%	1.78		0.00		
Primary Treatment					
AS	1.00	-	-		
Radical	0.50	0.38-0.67	0.00		
ADT	2.48	1.92-3.20	0.00		
		Non Prostate Cancer Morta			
Age FP age-69.87	1.13	1.12-1.14	0.00		
Comorbidity Score					






Figure 1: Calibration curves comparing observed and predicted PCa (left), non-prostate cancer (center) and overall deaths (right) at 10 years amongst the validation cohort.




Figure 2: Area under the ROC curves for PCa-specific mortality (left) and overall mortality (right) within the Singaporean validation cohort. Comparisons are made between PREDICT, the UCSF-CAPRA Score² and the 2018-updated NCCN risk-stratification score.³





Table 2: Hazard ratios, p values and coefficients of variables included in the PCSM and NPCM models. (FP = Fractional Polynomial, the function is displayed beneath)								
	Prostate Cancer Specific Mortality							
	HR	95%CI	Р	, Coef.	SE			
Age FP (age/10)^3 -341.16	1.003	1.002-1.003	0.000	0.003	0.00			
PSA FP In((psa+1)/100)+1.6364	1.204	1.092-1.328	0.000	0.186	0.05			
Grade group								
1	1.00	-	-	-	-			
2	1.32	1.06-1.65	0.01	0.28	0.11			
3	1.73	1.36-2.19	0.00	0.55	0.12			
4	2.10	1.63-2.69	0.00	0.74	0.13			
5	3.93	3.15-4.89	0.00	1.37	0.11			
T stage								
1	1.00	-	-	-	-			
2	1.18	1.01-1.37	0.04	0.16	0.08			
3	1.49	1.23-1.80	0.00	0.40	0.10			
4	1.88	1.14-3.13	0.01	0.63	0.26			
Percentage positive cores (F	PPC)							
<50%	0.54		0.00	-0.62				
≥50%	1.78		0.00	0.58				
Primary Treatment								
AS	1.00	-	-	-	-			
Radical	0.50	0.38-0.67	0.00	-0.68	0.14			
ADT	2.48	1.92-3.20	0.00	0.91	0.13			
	Non Prostate Cancer Mortality							
Age FP age-69.87	1.13	1.12-1.14	0.00	0.12	0.00			
Comorbidity Score								
1+	1.89	1.67-2.14	0.00	0.64	0.06			

.2 .4 .6 Observed probability of Overall death


15year overall mortality



RESULTS

respectively.

PCSM and overall mortality respectively.



Contact Information

David Thurtle: dt433@cam.ac.uk Vincent Gnanapragasam: vjg29@cam.ac.uk References

- May S et al. simplified method of calculating an overall goodness-of-fit test for the Cox model. Lifetime Data Anal.

2 - Cooperberg et al. Risk assessment for PCa metastasis and mortality at the time of diagnosis. J Natl Cancer Inst. 2009:101(12):878-887

3 – National Comprehensive Cancer Network (NCCN) Guidelines Version1.2018 www.nccn.org